Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825249 | 1.00 | PPARG (0.42) | PPARGCES2CES1ADRB1ADRA2A | |
| SCHEMBL7523840 | 1.00 | PPARG (0.42) | PPARGCES2CES1ADRB1ADRA2A | |
| SCHEMBL8746416 | 1.00 | PPARG (0.42) | PPARGCES2CES1ADRB1ADRA2A | |
| SCHEMBL8746393 | 0.98 | CES2 (0.42) | PPARGCES2CES1ADRB1ADRA2A | |
| SCHEMBL7786189 | 0.93 | CES2 (0.44) | PPARGCES2CES1ADRB1ADRA2A | |
| SCHEMBL7526784 | 0.93 | PPARG (0.38) | PPARGCES2CES1ADRB1ADRA2A | |
| SCHEMBL10091381 | 0.88 | CES2 (0.45) | CES2CES1ADRB1ADRA2AADRB3 | |
| SCHEMBL26326732 | 0.86 | PPARG (0.47) | PPARGCES2CES1CSNK1ESPHK1 | |
| SCHEMBL4910363 | 0.84 | PPARG (0.45) | PPARGCES2CES1CSNK1ESPHK1 | |
| SCHEMBL30557985 | 0.84 | PPARG (0.45) | PPARGCES2CES1CSNK1ESPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| WO-2006043149-A9 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET SOC CIV (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | disclosed |
| US-5683623-A | FERROELECTRIC LIQUID CRYSTALS CELLS AND DEVICES FOR ELECTROOPTICAL APPARATUS | CENTRAL RESEARCH LABORATORIES LIMITED (GB) | 1997-11-04 | — | — | US | disclosed |
| EP-0662114-B1 | DIOXANE DERIVATIVES | CENTRAL RESEARCH LAB LTD (GB) | 1997-02-19 | — | — | EP | disclosed |
| EP-0662114-A1 | DIOXANE DERIVATIVES. | CENTRAL RESEARCH LAB LTD (GB) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994006885-A1 | DIOXANE DERIVATIVES | CENTRAL RESEARCH LABORATORIES LIMITED (GB) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | PPARG 478/4885CES2 3929/4885CES1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.